<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-105728</identifier>
<setSpec>1576-1959</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Smoking cessation and diabetes mellitus</dc:title>
<dc:description xml:lang="en">Objectives. The principal objective of the study was to analyze the abstinence rate in diabetic smokers from the Diabetes Unit, treated with pharmacological therapy and brief psychological counseling, who were also given self-help information material. Methodology. An analytic, longitudinal and prospective study was conducted. The participants were diabetics who smoked. They were informed that the synergic action of diabetes and smoking increased both morbidity and mortality and all were offered help to quit smoking. The following inclusion criteria were established: being diabetic, of legal age, smoker of cigarettes or any other tobacco-derived product daily, and being in the preparation phase in the abandonment process. The intervention program included obtaining a Clinical History of the Smoking habit and the associated comorbidity was also investigated. First line drugs authorized by the FDA (TSN, bupropion and varenicline) were used plus brief psychological support for a period of 8-12 weeks. The program consisted in 7 visits (baseline visit, weeks 2 and 4, 2nd, 3rd and 4th months, and finally at 52 weeks. Results. A total of 96 patients, 68 (71%) of whom were male, participated. Mean age was 53.1 years. Mean cigarette consumption was 29.7 cig/day. Mean age of onset was at about 16 years. Cooximetry was 27.8 ppm. The first cigarette was consumed in less than 5 minute by 19.8%, in less than 30 minutes by 45.8% and more than 30 minutes by 34.4%. Abstinence after two weeks of initiation of treatment was varenicline 58%; TSN 52% and bupropion 49%, confirmed with the cooximetry (&lt;10 ppm). Abstinence at the end of follow-up at week 52 was: those treated with varenicline (32%); with nicotine patches 38%; with bupropion 33%. Conclusions. Cigarette smoking was high. Severe dependence was present in more than 65%, with lightening up of the first cigarette in less than 30 minutes. Global abstinence rate at 52 weeks was 32.2%. In spite of the risk factors supposed from smoking in diabetes, there are very limited studies on the management of smoking habit in this subgroup of patients. Smoking cessation should be an essential component in the comprehensive treatment of the diabetic patient who smokes (AU)</dc:description>
<dc:creator>Vaquero Lozano, P</dc:creator>
<dc:creator>León Carralafuente, E</dc:creator>
<dc:creator>Granda Orive, J. I. de</dc:creator>
<dc:creator>Garrido Martínez, R</dc:creator>
<dc:creator>Saavedra Blanco, M. A</dc:creator>
<dc:creator>Jiménez Ruiz, C. A</dc:creator>
<dc:creator>Solano Reina, S</dc:creator>
<dc:creator>Solano García-Tenorio, R</dc:creator>
<dc:creator>López Ruiz, T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. El objetivo principal del estudio fue analizar la tasa de abstinencia en fumadores diabéticos procedentes de la Unidad de Diabetes, tratados con terapia farmacológica y breve asesoramiento psicológico, a los que además se les entregó material informativo de autoayuda. Metodología. Estudio analítico, longitudinal y prospectivo. Los participantes eran diabéticos fumadores, se les informó que la acción sinérgica de la diabetes y el tabaco incrementa tanto la morbilidad como la mortalidad, y a todos se les ofreció ayuda para dejar de fumar. Se establecieron los siguientes criterios de inclusión: ser diabético, mayor de edad, consumo de cigarrillos o cualquier otro producto derivado del tabaco a diario, y encontrarse en la fase de preparación en el proceso de abandono. El programa de intervención incluía la realización de la Historia clínica de Tabaquismo, y también se investigó la comorbilidad asociada. Se utilizaron los fármacos de 1ª línea autorizados por la FDA (TSN, bupropion y vareniclina), más breve soporte psicológico durante un periodo de 8-12 semanas. El programa consistía en 7 visitas (visita basal; semanas 2ª y 4ª; 2º, 3º y 4º mes; y finalmente a la 52ª semana). Resultados. Participaron 96 pacientes, 68 (71%) eran varones. La media de edad era de 53,1 años. El consumo medio de cigarrillos fue de 29,7 cig./día. La edad media de inicio se situaba en torno a los 16 años. La cooximetría era de 27,8 ppm. El 19,8% consumía el 1er cigarrillo en menos de 5 minutos, el 45,8% en menos de 30 minutos, y el 34,4%, en más de 30 minutos. La abstinencia después de dos semanas del comienzo del tratamiento (vareniclina 58%, TSN 52% y bupropion 49%), confirmado con la cooximetría (&lt;10 ppm). La abstinencia al final del seguimiento en la 52ª semana: los que fueron tratados con vareniclina (32%); con parches de nicotina 38%; con bupropion 33%. Conclusiones. El consumo de cigarrillos era elevado. Presentaban una dependencia severa, más del 65% encendía el 1º cigarrillo en menos de 30 minutos. La tasa global de abstinencia a la 52ª semana fue del 32,2%. A pesar del aumento del factor de riesgo que supone fumar en la diabetes, existen estudios muy limitados sobre el manejo del tabaquismo en este subgrupo de pacientes. El abandono del tabaquismo debe ser un componente esencial en el tratamiento integral del paciente diabético fumador (AU)</dc:description>
<dc:source>Prev. tab;14(3): 105-111, jul.-sept. 2012. tab, ilus</dc:source>
<dc:identifier>ibc-105728</dc:identifier>
<dc:title xml:lang="es">Abandono del tabaco y diabetes mellitus</dc:title>
<dc:subject>^d^s22056</dc:subject>
<dc:subject>^d33882^s22045</dc:subject>
<dc:subject>^d33882^s22056</dc:subject>
<dc:subject>^d28418</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23925^s22080</dc:subject>
<dc:subject>^d54830^s22074</dc:subject>
<dc:subject>^d13761^s22012</dc:subject>
<dc:subject>^d13761^s22056</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d23925^s22054</dc:subject>
<dc:subject>^d14417^s22083</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d3942^s22056</dc:subject>
<dc:subject>^d3942^s22054</dc:subject>
<dc:subject>^d38644^s22056</dc:subject>
<dc:subject>^d30220^s22073</dc:subject>
<dc:subject>^d14417^s22054</dc:subject>
<dc:subject>^d33882^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201209</dc:date>
</metadata>
</record>
</ibecs-document>
